Homozygous Familial Hypercholesterolemia - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: H9F63C345CFBEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Homozygous Familial Hypercholesterolemia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Homozygous Familial Hypercholesterolemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Homozygous Familial Hypercholesterolemia Understanding

The DelveInsight Homozygous Familial Hypercholesterolemia epidemiology report gives a thorough understanding of the Homozygous Familial Hypercholesterolemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Homozygous Familial Hypercholesterolemia in the US, Europe, and Japan. The report covers the detailed information of the Homozygous Familial Hypercholesterolemia epidemiology scenario in seven major countries (US, EU5, and Japan).

Homozygous Familial Hypercholesterolemia Epidemiology Perspective by DelveInsight

The Homozygous Familial Hypercholesterolemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Homozygous Familial Hypercholesterolemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Homozygous Familial Hypercholesterolemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Homozygous Familial Hypercholesterolemia Detailed Epidemiology Segmentation

The Homozygous Familial Hypercholesterolemia epidemiology covered in the report provides historical as well as forecasted Homozygous Familial Hypercholesterolemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Homozygous Familial Hypercholesterolemia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Homozygous Familial Hypercholesterolemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Homozygous Familial Hypercholesterolemia Epidemiology Report and Model provide an overview of the global trends of Homozygous Familial Hypercholesterolemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Homozygous Familial Hypercholesterolemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Homozygous Familial Hypercholesterolemia
• The report provides the segmentation of the Homozygous Familial Hypercholesterolemia epidemiology

Report Highlights

• 11-year Forecast of Homozygous Familial Hypercholesterolemia epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Homozygous Familial Hypercholesterolemia
• Cases of Homozygous Familial Hypercholesterolemia by Mutation Types
• Homozygous Familial Hypercholesterolemia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Homozygous Familial Hypercholesterolemia?
• What are the key findings pertaining to the Homozygous Familial Hypercholesterolemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Homozygous Familial Hypercholesterolemia across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Homozygous Familial Hypercholesterolemia?
• What are the currently available treatments of Homozygous Familial Hypercholesterolemia?

Reasons to buy

The Homozygous Familial Hypercholesterolemia Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Homozygous Familial Hypercholesterolemia market
• Quantify patient populations in the global Homozygous Familial Hypercholesterolemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Homozygous Familial Hypercholesterolemia therapeutics in each of the markets covered
• Understand the magnitude of Homozygous Familial Hypercholesterolemia population by its epidemiology
• The Homozygous Familial Hypercholesterolemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

3. HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Homozygous Familial Hypercholesterolemia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Homozygous Familial Hypercholesterolemia Treatment and Management
6.2. Homozygous Familial Hypercholesterolemia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Homozygous Familial Hypercholesterolemia Epidemiology in 7MM (2019-2032)
Table 2: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Homozygous Familial Hypercholesterolemia Epidemiology in the United States (2019-2032)
Table 4: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Homozygous Familial Hypercholesterolemia Epidemiology in Germany (2019-2032)
Table 6: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Homozygous Familial Hypercholesterolemia Epidemiology in France (2019-2032)
Table 8: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Homozygous Familial Hypercholesterolemia Epidemiology in Italy (2019-2032)
Table 10: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Homozygous Familial Hypercholesterolemia Epidemiology in Spain (2019-2032)
Table 12: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Homozygous Familial Hypercholesterolemia Epidemiology in the United Kingdom (2019-2032)
Table 14: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Homozygous Familial Hypercholesterolemia Epidemiology in Japan (2019-2032)
Table 16: Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Homozygous Familial Hypercholesterolemia Epidemiology in 7MM (2019-2032)
Figure 2 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Homozygous Familial Hypercholesterolemia Epidemiology in the United States (2019-2032)
Figure 4 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Homozygous Familial Hypercholesterolemia Epidemiology in Germany (2019-2032)
Figure 6 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Homozygous Familial Hypercholesterolemia Epidemiology in France (2019-2032)
Figure 8 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Homozygous Familial Hypercholesterolemia Epidemiology in Italy (2019-2032)
Figure 10 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Homozygous Familial Hypercholesterolemia Epidemiology in Spain (2019-2032)
Figure 12 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Homozygous Familial Hypercholesterolemia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Homozygous Familial Hypercholesterolemia Epidemiology in Japan (2019-2032)
Figure 16 Homozygous Familial Hypercholesterolemia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report